Research compounds connected with growth-hormone signalling or body-composition claims, with evidence and product-quality limits made visible.
This is a discovery grouping, not a treatment category. Open a profile to see the exact evidence, risks, forms, routes, and U.S. status.
Published profiles · U.S. context · no rankings.
Topic orientation
This hub covers research connected with growth-hormone-releasing pathways, secretagogues, fragments, and body-composition claims. It is a reference grouping, not evidence that the profiles are equivalent or that a claimed outcome is established.
CJC-1295 with DAC and CJC-1295 without DAC are separate profile subjects. Evidence for the albumin-binding DAC molecule cannot be transferred to the defined non-DAC form or to an ambiguously labeled product.
Early human studies of some profiles measured growth-hormone or IGF-I changes in narrow settings. A pharmacodynamic signal does not establish clinical benefit, appropriate use, or long-term safety.
Sermorelin includes historical Geref information, but withdrawn historical approvals do not validate current preparations or wellness claims. Read each profile’s current U.S. status and formulation notes directly.
Useful entry points
These links are reading paths, not rankings. Open the full profile for its source-scoped evidence and limitations.
Open both profiles when the name appears in a source or product description; the modification changes the identity and the evidence that can be discussed.
Ipamorelin and sermorelin have different evidence histories, regulatory contexts, and unresolved questions despite overlapping search language.
AOD-9604 is a defined growth-hormone-related fragment with its own evidence and safety uncertainties; it is not a proxy for growth hormone or an approved weight-management treatment.
Published profile index
Search or filter the published entries below. Filters describe the source record; they do not tell you what is suitable.
5 published profiles
